Gomes Beatriz, Vale Nuno
PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.
School of Engineering, Universidade do Minho, Campus de Azurém, 4800-058 Guimarães, Portugal.
Curr Oncol. 2025 May 26;32(6):305. doi: 10.3390/curroncol32060305.
Breast cancer is the leading cause of death among women, and its treatment often involves chemotherapy and hormone therapy, which can compromise bone mineral density (BMD). Tamoxifen, a selective estrogen receptor modulator, has different effects depending on the patient's hormonal status. On the one hand, in postmenopausal women, it has a protective effect on BMD; on the other hand, in premenopausal women, it can accelerate bone loss, increasing the risk of osteoporosis and fractures. The reduction in estrogen levels during treatment is a key factor in this bone loss. This review underscores the importance of early risk assessment and regular monitoring of bone mineral density, along with the adoption of individualized pharmacological and non-pharmacological strategies, such as calcium and vitamin D supplementation and physical exercise, to preserve bone health in premenopausal women with breast cancer undergoing endocrine therapy.
乳腺癌是女性死亡的主要原因，其治疗通常涉及化疗和激素疗法，这可能会损害骨密度（BMD）。他莫昔芬是一种选择性雌激素受体调节剂，其效果因患者的激素状态而异。一方面，在绝经后女性中，它对骨密度有保护作用；另一方面，在绝经前女性中，它会加速骨质流失，增加骨质疏松症和骨折的风险。治疗期间雌激素水平的降低是这种骨质流失的关键因素。本综述强调了早期风险评估和定期监测骨密度的重要性，同时采用个性化的药物和非药物策略，如补充钙和维生素D以及体育锻炼，以保护接受内分泌治疗的绝经前乳腺癌女性的骨骼健康。
